TY  - JOUR
AU  - Moreno, Victor
AU  - Roda, Desamparados
AU  - Pikiel, Joanna
AU  - Trigo, Jose
AU  - Bosch-Barrera, Joaquim
AU  - Drew, Yvette
AU  - Kristeleit, Rebecca
AU  - Hiret, Sandrine
AU  - Bajor, David L
AU  - Cruz, Patricia
AU  - Beck, J Thaddeus
AU  - Ghosh, Srimoyee
AU  - Dabrowski, Christine
AU  - Antony, Grace
AU  - Duan, Tao
AU  - Veneris, Jennifer
AU  - Zografos, Eleftherios
AU  - Subramanian, Janakiraman
PY  - 2022
DO  - 10.1016/j.cllc.2022.05.013
UR  - http://hdl.handle.net/10668/22104
T2  - Clinical lung cancer
AB  - Dostarlimab is an anti-programmed cell death protein-1 antibody being evaluated in recurrent/advanced solid tumors, including non-small cell lung cancer (NSCLC), in the ongoing Phase I, multi-center, open-label, 2-part (dose escalation and cohort...
LA  - en
PB  - Elsevier
KW  - Cancer immunity
KW  - Immune checkpoint inhibitors
KW  - Lung neoplasms
KW  - PD-1
KW  - Treatment outcome
KW  - Humans
KW  - Antibodies, monoclonal, humanized
KW  - B7-H1 Antigen
KW  - Carcinoma, non-small-cell lung
KW  - Immune checkpoint inhibitors
KW  - Lung neoplasms
KW  - Neoplasm recurrence, local
KW  - Clinical trials, phase I as topic
TI  - Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
TY  - research article
VL  - 23
ER  -